Biotech Values

[DewDiligence]

The only reason I can see to be gun-shy about the “new” ABT (post-ABBV-spinoff) is that there has recently been some very heavy insider selling…

Miles White (CEO):
http://www.sec.gov/Archives/edgar/data/1800/000117911012015702/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012015703/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012015704/xslF345X03/edgar.xml

Heather Mason, SVP (Diabetes Care):
http://www.sec.gov/Archives/edgar/data/1800/000117911012012395/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012012394/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012012393/xslF345X03/edgar.xml

Michael Warmuth, SVP (Established Products [i.e. branded generics]):
http://www.sec.gov/Archives/edgar/data/1800/000117911012013059/xslF345X03/edgar.xml

Brian Blaser, EVP (Diagnostics):
http://www.sec.gov/Archives/edgar/data/1800/000117911012015434/xslF345X03/edgar.xml

John Landgraf, EVP (Nutritional Products)
http://www.sec.gov/Archives/edgar/data/1800/000117911012013703/xslF345X03/edgar.xml

Stephen Fussell, SVR (HR):
http://www.sec.gov/Archives/edgar/data/1800/000117911012015433/xslF345X03/edgar.xml


All told, that’s a lot of selling, especially by Mr. White and Ms. Mason.


There has also been a little selling by one insider who will end up with ABBV after the split…Carlos Alban, SVP:
http://www.sec.gov/Archives/edgar/data/1800/000117911012014554/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012014369/xslF345X03/edgar.xml
http://www.sec.gov/Archives/edgar/data/1800/000117911012014151/xslF345X03/edgar.xml